---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-251994"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-06-01T23:13:20+00:00"
generated_at: "2026-06-02T10:15:55.418571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73

## Summary
- Holder exercises 1,172,414 existing warrants at reduced $1.73/share for ~$2M cash gross proceeds.
- Company issues new warrant for up to 2,344,828 shares at $1.73, exercisable after stockholder approval, expiring May 29, 2028.
- Placement agent H.C. Wainwright receives warrants for 82,069 shares at $2.1625 per share.
- Company to file resale registration statement within 30 days; use best efforts to effect within 45 or 75 days.
- Existing warrants originally issued in November 2025 at $3.50 exercise price.

## SEC filing metadata
- accession: 0001193125-26-251994
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-06-01T23:13:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/d105562d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-251994
- JSON: https://secwatch.observer/filing/0001193125-26-251994.json
- Plain text: https://secwatch.observer/filing/0001193125-26-251994.txt

## Source-grounded claims
- claim_id: ab9d3c4d86668ce04a6c3c371ad4e715e0876cef
  claim: Tempest Therapeutics, Inc. entered into Inducement Letter with a holder of certain existing warrants to purchase shares of the Company’s common stock valued at approximately $2.0 million (effective 2026-05-28).
  evidence_excerpt: On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000119312526251994/0001193125-26-251994-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.